NEO-HYDELTRASOL Drug Patent Profile
✉ Email this page to a colleague
When do Neo-hydeltrasol patents expire, and when can generic versions of Neo-hydeltrasol launch?
Neo-hydeltrasol is a drug marketed by Merck and is included in one NDA.
The generic ingredient in NEO-HYDELTRASOL is neomycin sulfate; prednisolone sodium phosphate. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; prednisolone sodium phosphate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEO-HYDELTRASOL?
- What are the global sales for NEO-HYDELTRASOL?
- What is Average Wholesale Price for NEO-HYDELTRASOL?
Summary for NEO-HYDELTRASOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 10 |
| DailyMed Link: | NEO-HYDELTRASOL at DailyMed |
Recent Clinical Trials for NEO-HYDELTRASOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Oncology Group | Phase 2 |
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Children's Oncology Group | Phase 1/Phase 2 |
US Patents and Regulatory Information for NEO-HYDELTRASOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | NEO-HYDELTRASOL | neomycin sulfate; prednisolone sodium phosphate | OINTMENT;OPHTHALMIC | 050378-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
